| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019504416 |
| P356 | DOI | 10.2165/00003495-200262150-00001 |
| P698 | PubMed publication ID | 12381217 |
| P5875 | ResearchGate publication ID | 11079782 |
| P2093 | author name string | Charles A Peloquin | |
| P2860 | cites work | Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids | Q24550662 |
| Role of individual drugs in the chemotherapy of tuberculosis | Q28138632 | ||
| Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications | Q28146009 | ||
| Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids | Q28200162 | ||
| Tuberculosis: latency and reactivation | Q28201426 | ||
| The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis | Q28362898 | ||
| Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study | Q30605903 | ||
| The role of fluoroquinolones in tuberculosis today | Q32058584 | ||
| Adverse effects of antituberculosis drugs | Q33478562 | ||
| Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis | Q33588734 | ||
| Gatifloxacin | Q33768758 | ||
| Rifapentine: its role in the treatment of tuberculosis | Q33779876 | ||
| Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption | Q33792259 | ||
| The molecular basis of isoniazid resistance in Mycobacterium tuberculosis | Q33849234 | ||
| Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics | Q33871466 | ||
| Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids | Q33871989 | ||
| Goal-oriented, model-based drug regimens: setting individualized goals for each patient | Q33941123 | ||
| Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors | Q33946915 | ||
| Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis | Q33954713 | ||
| Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials | Q34296734 | ||
| Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention | Q34340511 | ||
| Increased incidence of tuberculosis in patients undergoing hemodialysis | Q71594405 | ||
| Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis | Q72319834 | ||
| Malabsorption of antimycobacterial medications | Q72923668 | ||
| AIDS and TB drug absorption | Q73274825 | ||
| Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection | Q73611185 | ||
| Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase | Q73633811 | ||
| The pharmacokinetics of oral rifampicin in AIDS patients | Q74199636 | ||
| Tuberculosis drug serum levels | Q74231109 | ||
| The latent tuberculosis bacillus (I'll let you know if I ever meet one) | Q74253950 | ||
| Once-daily and twice-daily dosing of p-aminosalicylic acid granules | Q74529437 | ||
| Serum concentrations of the antimycobacterial drugs | Q74576164 | ||
| Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients | Q74576185 | ||
| Development of rifapentine: the way ahead | Q77124255 | ||
| Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy | Q77190898 | ||
| The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol | Q77399732 | ||
| Therapeutic drug monitoring in antituberculosis chemotherapy | Q77436715 | ||
| Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors | Q77501492 | ||
| Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention | Q77535514 | ||
| Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. | Q34442450 | ||
| Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. | Q34483697 | ||
| Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids | Q34490001 | ||
| Pharmacological issues in the treatment of tuberculosis | Q34497277 | ||
| Rifampin and rifabutin drug interactions: an update | Q34628553 | ||
| Therapeutic drug monitoring in HIV infection: current status and future directions | Q34660139 | ||
| Low antituberculosis drug concentrations in patients with AIDS. | Q34735748 | ||
| Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. | Q35136143 | ||
| Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide | Q35139398 | ||
| AIDS enteropathy | Q35462384 | ||
| Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. | Q37778150 | ||
| The clinical pharmacokinetics of levofloxacin | Q37883517 | ||
| A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis | Q39449544 | ||
| Basic Mechanisms of Chemotherapy | Q39577659 | ||
| Pharmacokinetics and Metabolism of Rifampin in Humans | Q40161641 | ||
| Clinical pharmacokinetics of the antituberculosis drugs | Q40196353 | ||
| Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes | Q40905450 | ||
| Using therapeutic drug monitoring to dose the antimycobacterial drugs | Q41428779 | ||
| An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy | Q43556083 | ||
| Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids | Q43805866 | ||
| Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions | Q43809469 | ||
| Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors | Q45738784 | ||
| Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis | Q45742395 | ||
| Does AIDS impair the absorption of antituberculosis agents? | Q46257181 | ||
| Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea | Q46325159 | ||
| Rekindling old controversy on elusive lair of latent tuberculosis | Q46668543 | ||
| Risk of tuberculosis in dialysis patients: a population-based study. | Q50637060 | ||
| The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. | Q53923232 | ||
| Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. | Q54171121 | ||
| Drug malabsorption and resistant tuberculosis in HIV-infected patients. | Q54180223 | ||
| Pharmacokinetic evaluation of para-aminosalicylic acid granules. | Q54218757 | ||
| Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection | Q56485907 | ||
| Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease | Q58321699 | ||
| Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection | Q58826842 | ||
| National surveillance of dialysis associated diseases in the United States, 1995 | Q64133364 | ||
| Malabsorption of antituberculosis medications by a patient with AIDS | Q67582614 | ||
| Two three-month treatment regimens for pulmonary tuberculosis | Q68278546 | ||
| Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention | Q69371769 | ||
| Rifampicin raw material characteristics and their effect on bioavailability | Q69648193 | ||
| Tuberculosis in renal failure: a high incidence in patients born in the Third World | Q70027938 | ||
| Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome | Q70082718 | ||
| A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association | Q70174464 | ||
| Enteropathy associated with the acquired immunodeficiency syndrome | Q70609075 | ||
| P433 | issue | 15 | |
| P921 | main subject | tuberculosis | Q12204 |
| P304 | page(s) | 2169-2183 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Therapeutic drug monitoring in the treatment of tuberculosis | |
| P478 | volume | 62 |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q38547708 | A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children. |
| Q58578267 | A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs |
| Q41102009 | A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. |
| Q38639630 | A review of the use of ethionamide and prothionamide in childhood tuberculosis |
| Q35867335 | A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. |
| Q35745991 | A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets |
| Q30353049 | Advances in the diagnosis and treatment of tuberculosis. |
| Q38837774 | Adverse effects of oral second-line antituberculosis drugs in children. |
| Q44905354 | Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases |
| Q36998032 | Antituberculosis drug-induced hepatotoxicity: concise up-to-date review |
| Q38533435 | Antituberculosis drugs in children |
| Q37810481 | Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs |
| Q30415943 | Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania |
| Q46448545 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis |
| Q42635508 | Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program |
| Q37133651 | Central nervous system tuberculosis: pathogenesis and clinical aspects |
| Q83966961 | Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs |
| Q37305611 | Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013. |
| Q42335970 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines |
| Q36290609 | Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters |
| Q42688154 | Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough? |
| Q37692457 | Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. |
| Q47223914 | Clinical response of tuberculosis patients, a prospective cohort study |
| Q42201109 | Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. |
| Q38235444 | Current bioanalytical methods for pharmacokinetic studies of drugs used in neglected tropical diseases |
| Q38763608 | Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis |
| Q52669182 | Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations. |
| Q41908884 | Design and Optimization of a New Voltammetric Method for Determination of Isoniazid by Using PEDOT Modified Gold Electrode in Pharmaceuticls |
| Q90587475 | Determinants of serum concentration of first-line anti-tuberculosis drugs from China |
| Q39630732 | Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma |
| Q38700929 | Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis |
| Q80706448 | Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2 |
| Q37339268 | Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests |
| Q61766644 | Drug-Resistant Tuberculosis |
| Q35028452 | Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels |
| Q37722677 | Drugs and pharmaceuticals: management of intoxication and antidotes. |
| Q30415746 | Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. |
| Q92486406 | Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis |
| Q35912691 | Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears |
| Q30274831 | Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. |
| Q57789767 | Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment |
| Q34597564 | Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients |
| Q43203258 | Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis |
| Q42358808 | Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro |
| Q64968288 | Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations. |
| Q38673843 | Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children |
| Q34561741 | Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes |
| Q37291363 | Extensively drug-resistant tuberculosis: new strains, new challenges |
| Q45131685 | Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection. |
| Q37626582 | Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance |
| Q47954072 | Failure to reach therapeutic levels of rifampicin and isoniazid by recommended dosages. |
| Q43060441 | Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs |
| Q37287701 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients |
| Q33576421 | Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences |
| Q37784382 | Hepatotoxic effects of therapies for tuberculosis |
| Q37613267 | Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management |
| Q34981779 | Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection |
| Q34922554 | Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis |
| Q41901707 | In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis |
| Q45741529 | Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with Mycobacterium bovis infection |
| Q38701604 | Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes |
| Q42245443 | Initial combination of injectable and oral anti-tuberculosis agents for the treatment of severe disseminated tuberculosis |
| Q30251497 | Insights into the pharmacokinetic properties of antitubercular drugs. |
| Q34458735 | Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial |
| Q34600493 | Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers |
| Q89163367 | Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients |
| Q38210065 | Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review |
| Q36958417 | Isoniazid hair concentrations in children with tuberculosis: a proof of concept study |
| Q36097299 | Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants |
| Q34729493 | Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients |
| Q58856447 | Lack of association between rifampicin plasma concentration and treatment-related side effects in osteoarticular infections |
| Q35778303 | Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB. |
| Q38860926 | Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda |
| Q42582004 | Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis |
| Q36122639 | Management of Severe Gastrointestinal Tuberculosis with Injectable Antituberculous Drugs |
| Q38040155 | Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. |
| Q37058166 | Management of multidrug-resistant tuberculosis: Update 2007. |
| Q43745618 | Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. |
| Q35978007 | Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis |
| Q28596775 | New anti-tuberculosis drugs and regimens: 2015 update |
| Q37694580 | Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis |
| Q64251790 | Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India |
| Q38865905 | Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. |
| Q30300207 | Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014 |
| Q36870689 | Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. |
| Q37287653 | Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease |
| Q46795433 | Peak plasma rifampicin level in tuberculosis patients with slow culture conversion |
| Q35859862 | Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis |
| Q35692736 | Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections |
| Q36068683 | Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure |
| Q38845761 | Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. |
| Q47332682 | Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? |
| Q33282527 | Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients |
| Q46271797 | Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs |
| Q40500659 | Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection |
| Q28550488 | Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania |
| Q36730120 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. |
| Q35860097 | Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers |
| Q33521011 | Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes |
| Q35270526 | Pharmacokinetics of ethionamide in children |
| Q53569108 | Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. |
| Q36969720 | Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients |
| Q35215680 | Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children |
| Q35598492 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. |
| Q91927814 | Pharmacokinetics of isoniazid: The good, the bad, and the alternatives |
| Q34298935 | Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis |
| Q51139486 | Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. |
| Q33797850 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. |
| Q35941434 | Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV |
| Q52684511 | Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay. |
| Q37263571 | Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus |
| Q30426583 | Plasma drug activity assay for treatment optimization in tuberculosis patients |
| Q30411475 | Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis |
| Q36482760 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis |
| Q37688266 | Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses |
| Q28553471 | Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting |
| Q41679231 | Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients |
| Q35666918 | Programmes and principles in treatment of multidrug-resistant tuberculosis |
| Q28552186 | Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis |
| Q28079207 | Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations |
| Q39030684 | Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis |
| Q36018761 | Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines |
| Q45151120 | Relationship between CES2 genetic variations and rifampicin metabolism |
| Q43183652 | Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future". |
| Q38244769 | Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults. |
| Q36214730 | Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly |
| Q37425851 | Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis |
| Q36705355 | Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis |
| Q38369608 | Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. |
| Q40180361 | Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics |
| Q38353565 | Safety and tolerability profile of second-line anti-tuberculosis medications |
| Q40800121 | Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana |
| Q37213037 | Serum drug concentrations predictive of pulmonary tuberculosis outcomes |
| Q90411653 | Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection |
| Q49355614 | Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis |
| Q42693597 | Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response |
| Q35167178 | Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study |
| Q28550707 | The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB |
| Q41647862 | The Use of Therapeutic Drug Monitoring in Complex Antituberculous and Antiretroviral Drug Dosing in HIV/Tuberculosis-Coinfected Patients |
| Q41679385 | The combined fixed-dose antituberculous drugs alter some reproductive functions with oxidative stress involvement in wistar rats |
| Q33291134 | The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis |
| Q56912878 | The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs |
| Q30427912 | Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA |
| Q36582619 | Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance |
| Q35487794 | Therapeutic drug monitoring in the treatment of active tuberculosis |
| Q38213320 | Therapeutic drug monitoring in the treatment of tuberculosis: an update |
| Q35640430 | Therapeutic drug monitoring of antimicrobials |
| Q44776728 | Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection |
| Q47998746 | Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration. |
| Q42281128 | Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. |
| Q36439006 | Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis |
| Q37185463 | Treatment of a tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs |
| Q34156234 | Tuberculosis and diabetes mellitus: convergence of two epidemics |
| Q37852382 | Tuberculosis at the human-animal interface: an emerging disease of elephants |
| Q40370209 | Tuberculosis in children undergoing hemodialysis |
| Q36238439 | Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues |
| Q83292700 | Tuberculosis pharmacotherapy: strategies to optimize patient care |
| Q44701899 | Tuberculosis-current therapeutic principles |
| Q26775974 | US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis |
| Q30411703 | Understanding pharmacokinetics to improve tuberculosis treatment outcome |
| Q28072205 | Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations |
| Q35767124 | Use of technetium(99m)-ciprofloxacin scan in Pott's spine to assess the disease activity |
| Q35120591 | Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients |
| Q40343208 | Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections |
Search more.